Beauchesne P, Bonner J A, Mornex F, Brunon J
Mayo clinic center, Rochester, MN, USA.
Cancer Radiother. 1999 Jan-Feb;3(1):57-64. doi: 10.1016/s1278-3218(99)80035-3.
Etoposide, a Topoisomerase II inhibitor agent, is currently being explored as a therapeutic agent for brain tumors. The aim of this experimental study was to compare the in vitro etoposide sensitivity of human glioma cells vs human squamous cell carcinoma (SCC) cells.
Twelve human cell lines (six malignant glioma cell lines and six head and neck SCC cell lines) were used for this comparative study. A standard colony formation assay was used to assess cell survival. Since Topoisomerase II is the critical target for etoposide, it was of interest to determine Topoisomerase II activity and etoposide induced inhibition of Topoisomerase II activity for the glioma cells vs the SCC cells.
Except for etoposide-induced inhibition of Topoisomerase II activity, no difference was found for etoposide sensitivity and Topoisomerase II activity between the both type of cells.
These results suggested that the Topoisomerase II reactive agents may prove to be clinically a useful drug for patients presenting with malignant gliomas.
拓扑异构酶II抑制剂依托泊苷目前正作为脑肿瘤治疗药物进行探索。本实验研究的目的是比较人胶质瘤细胞与人鳞状细胞癌（SCC）细胞对依托泊苷的体外敏感性。
本比较研究使用了12种人类细胞系（6种恶性胶质瘤细胞系和6种头颈部SCC细胞系）。采用标准集落形成试验评估细胞存活率。由于拓扑异构酶II是依托泊苷的关键靶点，因此确定胶质瘤细胞与SCC细胞的拓扑异构酶II活性以及依托泊苷诱导的拓扑异构酶II活性抑制情况很有意义。
除依托泊苷诱导的拓扑异构酶II活性抑制外，两种细胞在依托泊苷敏感性和拓扑异构酶II活性方面未发现差异。
这些结果表明，拓扑异构酶II反应性药物可能在临床上被证明是治疗恶性胶质瘤患者的有效药物。
